Release Date: April 28, 2025
Expiration Date: April 28, 2026
Activity Overview
This online, on-demand, virtual symposium brings together renowned experts in chronic kidney disease (CKD). In this educational program, these experts use a case-based format to discuss the use of HIF-PHIs for dialysis-dependent patients with CKD and anemia and ways that this new class of drugs fits into our current treatment protocols.
This educational activity is an archive of the live symposium held on March 16, 2025.
Target Audience
This educational activity is directed toward nephrologists and nephrology nurses. Other health care practitioners involved in managing patients with CKD will also find it useful.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the burden of anemia on patients with CKD
- Evaluate clinical trial data for HIF-PHIs for anemia in CKD
- Design individualized management plans for patients with anemia and CKD
Glenn M. Chertow, MD, MPH
Norman S. Coplon/Satellite Healthcare Professor of Medicine
Professor, by Courtesy, of Epidemiology and Population Health and Health Policy
Stanford University
Stanford, CA
Disclosures: Board of Directors: Satellite Healthcare, a nonprofit dialysis provider; Chair or Co-Chair of Trial Steering Committees: Akebia Therapeutics, AstraZeneca, CSL Behring, Sanifit, Vertex Pharmaceuticals; Adviser: Alexion, Applaud, Ardelyx, Calico Life Sciences, CloudCath, Durect, Eliaz Therapeutics, Miromatrix Medical, Outset Medical, Renibus Therapeutics, Unicycive Therapeutics, Data Safety Monitoring Boards: Bayer, Mineralys Therapeutics, Recor Medical.
Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN
Professor of Medicine
University of California, San Francisco
Fresno, CA
Disclosures: Consultant: CorMedix.
Preethi Yerram, MD
Professor of Medicine/Transplant Nephrologist
University of Missouri, Columbia
Columbia, MO
Disclosures: Other: AstraZeneca, CareDx, Fresenius Medical Care, GSK, Qsource.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
